Steven J. Romano - Jan 2, 2025 Form 3 Insider Report for Silence Therapeutics plc (SLN)

Role
EVP and Chief R&D Officer
Signature
/s/ Rhonda Hellums, Attorney-in-Fact
Stock symbol
SLN
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
3
Date filed
1/2/2025, 04:26 PM
Previous filing
Sep 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SLN Ordinary Shares 13K Jan 2, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLN Employee Share Option (Right to Buy) Jan 2, 2025 Ordinary Shares 48K $7.87 Direct F1
holding SLN Employee Share Option (Right to Buy) Jan 2, 2025 Ordinary Shares 300K $2.07 Direct F2
holding SLN Employee Share Option (Right to Buy) Jan 2, 2025 Ordinary Shares 48K $5.13 Direct F3
holding SLN Employee Share Option (Right to Buy) Jan 2, 2025 Ordinary Shares 450K $3.27 Direct F4
holding SLN Employee Share Option (Right to Buy) Jan 2, 2025 Ordinary Shares 225K $5.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vested or shall vest in equal monthly installments over a three-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F2 One fourth (1/4th) of the shares subject to the option vested on April 1, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.
F3 This option vested or shall vest in equal monthly installments over a three-year period measured from one month following September 14, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.
F4 This option vested or shall vest in equal monthly installments over a four-year period measured from one month following October 1, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.
F5 One fourth (1/4th) of the shares subject to the option shall vest on January 4, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.